IDUNNNCT07820813
bNAbs and Anti-PD-1 in HIV
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Sep 15, 2026 to Oct 7, 2026
- Study sites: 0 to 1
- Collaborators: 10 to 8
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Time from the day of stopping ART to the day of meeting criteria for loss of immunological control of HIV-1 (defined below)
Timeframe: 60 weeks
Secondary (7)
The safety and tolerability of the Investigational Medicinal Products (IMPs)
The frequency of post-interventional immunological control of HIV-1
The effect of the IMPs on HIV-1-specific T cells responses before, during and after the ATI
The effect of the IMPs on the intact HIV-1 reservoir before, during and after the ATI
The effect of the IMPs on the immune cell phenotype, activation and exhaustion
Show 2 moreShow less
The effect of autologous antibodies on post-interventional immunological control of HIV-1
bNAb sensitivity
Arms and interventions
A: bNAbs/anti-PD-1aExperimental
3BNC117-LS, 10-1074-LS and nivolumab
B: bNAbs/placeboActive comparator
3BNC117-LS, 10-1074-LS and placebo
Drugs: 3BNC117-LS, 10-1074-LS, Nivolumab
Other: Placebo
Sites
1 site in 1 country
- Aarhus University HospitalAarhus, Denmark